Use of Inspra in heart failure extended

Inspra (eplerenone) has been approved for use with standard therapy to reduce the risk of cardiovascular morbidity and mortality in adults with chronic heart failure (NYHA class II) and left ventricular ejection fraction (LVEF) 30% or less.

Left ventricular dysfunction (LVD) reduces cardiac output and increases the strain on the heart, causing increased morbidity and mortality | SCIENCE PHOTO LIBRARY
Left ventricular dysfunction (LVD) reduces cardiac output and increases the strain on the heart, causing increased morbidity and mortality | SCIENCE PHOTO LIBRARY

The aldosterone antagonist is already indicated for use in stable patients with left ventricular dysfunction (LVEF ≤40%) and clinical evidence of heart failure after recent MI.

EMPHASIS-HF trial results

The new indication was approved following a pivotal study in 2737 patients in 29 countries worldwide, comparing eplerenone (up to 50mg daily) plus standard optimal therapy to placebo plus standard optimal therapy in high-risk patients with NYHA class II heart failure and LVEF 35% or less. Results showed a 37% relative risk reduction with eplerenone in the rate of cardiovascular death or first hospitalisation for heart failure (p<0.001).

Eplerenone also reduced the secondary endpoints of hospitalisation for heart failure (–42%; p<0.001), all-cause mortality (–24%; p=0.008), cardiovascular mortality (–24%; p=0.01) and all-cause hospitalisation (–23%, p<0.001).

View Inspra drug record

Further information: Pfizer Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases